In a report released yesterday, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $22.50. The company's shares closed last Monday at $7.60, close to its 52-week low of $7.41. According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.1% and a 61.3% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Boston Scientific, and Merck & Company. Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $21.25, which is a 170.0% upside from current levels.
https://www.tipranks.com/news/blurbs/credit-suisse-thinks-coherus-biosciences-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Coherus BioSciences Charts.